Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

Aristotle Capital Boston disclosed in a Nov. 14 SEC filing that it sold 503,122 shares of Supernus Pharmaceuticals in Q3, trimming its stake to 305,273 shares valued at $14.6 million as of Sept. 30 (the sales represented roughly $10.9 million and Supernus was about 0.75% of 13F AUM). Supernus shares have rallied ~31% over the past year to $47.28 (market cap ~$2.7bn); operationally the company reported Q3 revenue up 9% year‑over‑year to $192.1m, strong growth across its four key products (collectively >50%), the first full quarter of ONAPGO sales and an upward revision to full‑year revenue guidance, but GAAP results swung to a loss due largely to acquisition-related costs and adjusted operating earnings declined despite ~ $280m cash on hand. The filing looks like portfolio rebalancing or profit‑taking after a strong share run rather than a clear loss of conviction, with ongoing integration and profitability risks remaining catalysts to monitor.

Analysis

Aristotle Capital Boston disclosed in an SEC filing that it sold 503,122 shares of Supernus Pharmaceuticals in Q3, reducing its stake to 305,273 shares valued at $14.6 million as of September 30; the sales represented roughly $10.9 million and left Supernus at about 0.75% of the fund’s 13F AUM. This transaction follows a period in which Supernus shares have rallied ~31% over the past year to $47.28, implying the trim is consistent with profit-taking or portfolio reallocation rather than an outright vote of no confidence.

Operationally, Supernus reported Q3 revenue of $192.1 million, up 9% year-over-year, driven by collective growth of more than 50% across its four key growth products, with ONAPGO delivering its first full quarter and the company raising full-year revenue guidance. Despite top-line momentum, TTM net income was negative $19.1 million and GAAP results swung to a loss largely because of acquisition-related costs tied to the Sage deal, while adjusted operating earnings declined, leaving profitability uneven even as cash on hand (~$280 million) provides flexibility.

The investor action and fundamentals together suggest a mixed risk/reward profile: revenue momentum and product launches are constructive catalysts, but integration costs, deteriorating adjusted operating earnings and valuation after the strong share run are material risks. Market-impact indicators are modest (market_impact_score ~0.25) so position flows from this single manager are unlikely to drive a sustained market move; active investors should watch near-term execution and cost-integration metrics for directional clarity.

Key Decisions for Investors

• Reassess current SUPN exposure and consider trimming or maintaining rather than initiating a full-sized new position given the ~31% one-year rally and Aristotle’s profit-taking
• Monitor upcoming quarterly results for adjusted operating earnings, Sage integration costs, and ONAPGO sales momentum; add incrementally only on clear signs of margin recovery or sustained revenue beats
• If keeping or adding exposure, size positions conservatively and use risk management (e.g., hedges or defined stop-loss levels) because GAAP losses and integration risk create meaningful downside despite solid revenue trends and ~$280m cash on hand